medigraphic.com

2013, Number 2

Rev Cubana Hematol Inmunol Hemoter 2013; 29 (2)

Modulator effect of ozone therapy over immune system activity

Díaz LJ, Macías AC, Menéndez CS

Language: Spanish
References: 44
Page:
PDF size: 91.40 Kb.


ABSTRACT

The employment of biological medicine has allowed the application of beneficial and systemic therapies where the body is treated as a whole. The ozone therapy is a modality of the biological medicine, it is a natural therapeutical procedure that has represented an extremely safe medical therapy, free from side effects, an effective and feasible method in the field of treatment of immunological diseases, with encouraging results for the social and economic impact that is generated after its application. There are experimental evidences that assert this statement. We hereby describe the immunomodulatory property of ozone therapy, the biological effects of the ozone on the cells of the immune system cells, other cellular types and different immune mediators.


REFERENCES

  1. Bocci V, Zanardi D M, Travagli V. Mechanisms of action and chemical-biological interactions between ozone and body compartments: a critical appraisal of the different administration routes. Current Drug Therapy 2009, 4: 159-73.

  2. Arencibia JR, Leyva Y, Collymore A, Araujo JA. Producción científica sobre aplicaciones terapéuticas del ozono en el Web of Science. ACIMED [revista en la Internet]. 2006 Feb; 14(1): Disponible en:http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1024- 94352006000100007&lng=es .

  3. Menéndez S. Mecanismos de acción biológica y efectos terapéuticos del ozono. En: Menéndez S, González R, Ladea OE, Hernández F, León OS, Díaz M. Ozono: Aspectos Básicos y Aplicaciones Clínicas. 1ra Ed. La Habana: CENIC; 2008. p. 4-107.

  4. Bocci V. Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res 2006; 37: 425-35.

  5. Bocci V, Borelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev. 2009; 29: 646-82.

  6. Travagli V, Zanardi I, Silvietti A, Bocci V. A physicochemical investigation on the effects of ozone on blood. Int J Biol Macromol. 2007; 41: 504-11.

  7. Larini A, Bocci V. Effects of ozone on isolated peripheral blood mononuclear cells. Toxicology in Vitro 2005 Feb; 19(1): 55-61.

  8. Abbas AK. Activation of lymphocytes. In: Abba AK, Lichtman A. Cellular and Molecular Immunology. 7ma ed. NY: WB Saunders Co. 2011. p. 203-24.

  9. Wikipedia. Sistema inmunitario. [citado 2012 agosto14] Disponible en:http://es.wikipedia.org/wiki/Sistema_inmunitario

  10. Travagli VV, Zanardei I, Silvietti A, Bocci V. A physicochemical investigation on the effect of ozone on blood. Intern. J. Biol. Macromol 2007; 41: 504-11.

  11. Huanqui P, Cruz M, Miranda A, Patrica P, Mamani R. Eficacia y seguridad del ozono ontraarticular en ambas rodillas refractaria al tratamiento. Rev. Perú Reum. 2006; 12(1): 21-6.

  12. Rhee SG, Bae YS, Lee SR, Kwon J. Hydrogen peroxide a key messengers that module protein phosphorylation through cysteine oxidation. Sci STKE 2000; Oct 10: 53.

  13. Li Q, Verma IM, . Nf-kB regulation in the immune system. Nat Rev Immunol. 2002 Oct; 2(10): 725-34.

  14. Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat. Immunol. 2002; 3: 1129-34.

  15. Bocci V, Taylor F. Ozone as Janus: This controversial gas can be toxic or medically useful. Health Sci. 2004; 13 (1): 3-11.

  16. Abbas AK. Cytokines- appendix II. In: Abba AK, Lichtman A. Cellular and Molecular Immunology. 7ma ed. NY: WB Saunders Company 2011. p. 501-4.

  17. Bocci V, Luzzi E, Corradeshi F, Paulesu L, Di Stefano A. Studies on the biological effects of ozone: 3. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res 1993 Apr; 12(2):121-6.

  18. Viebahn Haensler R, Andrew Lee A. Los mecanismos de acción del ozono médico. En: Viebahn Haensler R. El uso del Ozono en Medicina. 4ta ed. Heidelberg: Practical Handbook; 2002. p. 98-129.

  19. Pancer Z, Cooper MD.The evolution of adaptive immunity. Annu Rev Immunol 2006; 24: 497518.

  20. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood .2004; 112 (4):93545.

  21. Menéndez S. Propiedades terapéuticas del ozono. Rev. Cubana Farmacia 2002; 36(2):189-91.

  22. Casanova JL, Fischer C, Zhang SY, Abel L. Revisiting human primary immunodeficiency. J Int Med. 2008; 264: 115-27.

  23. Poplonyk SA. An overlapping syndrome of allergy and immune deficiency in children. J Allergy (Cairo) 2012; 2012:1-9.

  24. Bocci V, Zanardi I, Travagli V. Ozone acting on human blood yields a hermetic dose-response relationship. J Transl Med 2011; 9: 66-7.

  25. Bruce A, Johnson A, Lewis J, Raff M, Keith R, Walters P. Molecular Biology of the Cell. 4th Edition. New York and London: Garland Science; 2002.

  26. Cardile V, Jiang X, Russo A, Casella F, Renis M, Bindoni M. Effects of Ozone on Some Biological Activities of Cells in Vitro. Cell Biology Toxicol 2005; 11: 11-21.

  27. Garber, GE, Cameron DW. «The Use of Ozone-Treated Blood in the Therapy of Hiv- Infection and Immune Disease - a Pilot-Study of Safety and Efficacy.» Aids 1991; 5(8): 981-84.

  28. Díaz J, Martín N, Menéndez CS. Evaluación de la actividad inmunomoduladora del ozono sobre los leucocitos: in vivo e in vitro. Vaccimonitor 2011; 20 (1): 22-3.

  29. Travagli V, Zanardi I, Bernini P, Nepi S, Tenori L, Bocci V. Effects of ozone blood treatment on the metabolite profile of human blood. Int J Toxicol. 2010; 29: 165-74.

  30. Díaz J, Sardiñas G, Menéndez S, Macías C. Efecto inmunomodulador de la ozonoterapia en niños con deficiencia en la inmunidad mediada por fagocitos. Mediciego 2012; Vol. 18 (1): Disponible en:http://bvs.sld.cu/revistas/mciego/vol18_01_2012/articulos/t -9.html

  31. Centro de Investigaciones del Ozono. Compendio de estudios y aplicaciones del Ozono en Cuba (1980-2004) [CD-ROM]. La Habana: SOFTCAL-CENIC, 2005.

  32. Díaz J, Parés Y, Risco G. Aplicación de la ozonoterapia en la deficiencia Selectiva de IgA. Revista Cubana Hematol Inmunol Hemoter. 2009; 25(supl):265-301.

  33. Méndez IP, Montesino AC, Peña RC, Martínez GJ, Menéndez CS. Ozonoterapia sistémica e intraarticular en la artritis de la articulación temporo-mandibular por artritis reumatoide. Rev. CENIC 2010; 41[supl3]: 169-72.

  34. Tallon H, Jave F. Oxígeno-Ozonoterapia: una realidad Médica. Rev Soc Esp Dolor 2009; 16(03): 190-2.

  35. Carmona L. Ozonoterapia en Enfermedades Reumáticas. Reumatología Clínica 2006; 2(3): 119-23.

  36. Calunga JL, Paz AY, Menéndez SC, Martínez A, Hernández A. La ozonoterapia en pacientes con enfisema pulmonar. Rev. Med. Chile 2011; 139(4): 439-47.

  37. Hernández F, Calunga JL, Turrent J, Menéndez S, Montenegro A. Ozone therapy effects on blood biomarkers and lung function of asthma patients», Arch Med Res. 2005; 36(5):549-54.

  38. Bocci V. Ozonation of blood for the therapy of viral disease and immunodeficiencies. A hypothesis. Medical hypothesis 1992 Sep; 39(1): 30-4.

  39. PROMEDICA. Generadores de ozono para uso médico. Vías de administración. Madrid: José Bergamín. Actualizado [ 31/03/ 2008; citado 15/11/2011] [aprox. 2 pantallas]. Disponible en:http://www.promedica.com/admin.html .

  40. German Medical Association of Ozone Application in Prevention and Therapy. Guidelines for the Use of Ozone in Medicine [actualizado 10/3/2011; citado 3/8/2012] disponible en: http://www.ozonosan.eu/images/upload/File /Guidelines0309.pdf

  41. Bocci V, Borrelli, E, Corradeshi F, Valacchi, G. Systemic effects after colorectal insufflation of oxygen-ozone in rabbits. Int J Med Biol Environ.2000; 28: 109-13.

  42. Zaky S, Kamel SE, Hassan MS. Preliminary results of ozone therapy as a possible treatment for patients with chronic hepatitis C. J Altern Complement Med. 2011 Mar;17(3):259-63.

  43. Hernandez FA. To what extent does ozone therapy need a real biochemical control system? Assessment and importance of oxidative stress. Arch Med Res. 2007; 38(5):571-8.

  44. Schwartz A. La ozonoterapia y su fundamentación científica. Rev. Española de ozonoterapia 2012; 2(1): 163-98.




2020     |     www.medigraphic.com